We have located links that may give you full text access.
Cluster of non-toxigenic Corynebacterium diphtheriae infective endocarditis and rising background C. diphtheriae cases-Seattle, Washington 2020-2023.
Clinical Infectious Diseases 2024 Februrary 22
BACKGROUND: Non-toxigenic Corynebacterium diphtheriae (C. diphtheriae), often associated with wounds, can rarely cause infective endocarditis (IE). Five patients with C. diphtheriae IE were identified within 12 months at a Seattle-based hospital system. We reviewed prior C. diphtheriae positive cultures to determine if detections had increased over time and evaluated epidemiologic trends.
METHODS: We conducted a formal electronic health record search to identify all patients ≥ 18 years of age with C. diphtheriae detected in a clinical specimen (i.e. wound, blood, sputum) between September 1, 2020-April 1, 2023. We collected patient demographics, housing status, comorbidities, substance use history and level of medical care required at detection. We extracted laboratory data on susceptibilities of C. diphtheriae isolates, and on other pathogens detected at the time of C. diphtheriae identification.
RESULTS: Between September 1, 2020-April 1, 2023, 44 patients (median age 44 years) had a C. diphtheriae-positive clinical culture, with most detections occurring after March 2022. Patients were predominantly male (75%), White (66%), unstably housed (77%), and had a lifetime history of injecting drugs (75%). Most C. diphtheriae positive cultures were polymicrobial, including wound cultures from 36 (82%) patients and blood cultures from 6 (14%) patients, not mutually exclusive. Thirty-four patients (77%), including all five patients with C. diphtheriae IE, required hospital admission for C. diphtheriae or a related condition. Of the five patients with IE, three died of IE and one from COVID-19.
CONCLUSION: Findings suggest a high-morbidity outbreak disproportionately affecting patients who use substances and are unstably housed.
METHODS: We conducted a formal electronic health record search to identify all patients ≥ 18 years of age with C. diphtheriae detected in a clinical specimen (i.e. wound, blood, sputum) between September 1, 2020-April 1, 2023. We collected patient demographics, housing status, comorbidities, substance use history and level of medical care required at detection. We extracted laboratory data on susceptibilities of C. diphtheriae isolates, and on other pathogens detected at the time of C. diphtheriae identification.
RESULTS: Between September 1, 2020-April 1, 2023, 44 patients (median age 44 years) had a C. diphtheriae-positive clinical culture, with most detections occurring after March 2022. Patients were predominantly male (75%), White (66%), unstably housed (77%), and had a lifetime history of injecting drugs (75%). Most C. diphtheriae positive cultures were polymicrobial, including wound cultures from 36 (82%) patients and blood cultures from 6 (14%) patients, not mutually exclusive. Thirty-four patients (77%), including all five patients with C. diphtheriae IE, required hospital admission for C. diphtheriae or a related condition. Of the five patients with IE, three died of IE and one from COVID-19.
CONCLUSION: Findings suggest a high-morbidity outbreak disproportionately affecting patients who use substances and are unstably housed.
Full text links
Related Resources
Trending Papers
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.Seminars in Nephrology 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app